Related Experiment Video
Updated: Jul 30, 2025

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
The Intersection of Prostate Cancer and Hypertension: a Call to Action
Elena Dolmatova1, Nida Waheed1, Brian Michael Olson1
1Emory University School of Medicine, Atlanta, GA, USA.
Insights
Prostate cancer treatments can increase hypertension risk. This review covers hypertension incidence, mechanisms, and offers individualized blood pressure management strategies for prostate cancer patients.
Area of Science:
- Cardiovascular Medicine
- Oncology
- Pharmacology
Background:
- Improving prostate cancer survival increases the impact of comorbid cardiac conditions.
- Hypertension is a major cardiovascular risk factor, exacerbated by prostate cancer therapies.
- Prostate cancer treatments like GnRH agonists and novel hormonal agents can elevate blood pressure.
Purpose of the Study:
- To review the incidence and mechanisms of hypertension in prostate cancer patients.
- To provide recommendations for assessing and managing hypertension in this population.
- To propose individualized blood pressure goals considering patient comorbidities.
Main Methods:
- Literature review of existing evidence on hypertension in prostate cancer.
- Analysis of mechanisms linking prostate cancer treatments to hypertension.
- Development of clinical recommendations for hypertension management.
Main Results:
- Prostate cancer therapies are associated with increased hypertension risk.
- Individualized blood pressure targets are necessary, balancing 130/80 mmHg with frailty and other comorbidities.
- Comorbidities guide the selection of antihypertensive medications.
Conclusions:
- Hypertension is a critical concern in the growing population of prostate cancer survivors.
- Personalized hypertension management is essential for optimizing outcomes.
- Further research is needed to refine treatment strategies for this patient group.
Opinion Statement:
With improvements in treatment and survival from prostate cancer, comorbid cardiac conditions will significantly impact overall morbidity and mortality from prostate cancer. Hypertension is a well-established cardiovascular risk factor that increases the risk of heart failure, myocardial infarction, and stroke. Therapies used in the treatment of prostate cancer, including GnRH agonists, GnRH antagonists, enzalutamide, abiraterone, and others, can directly or indirectly increase the risk of hypertension. In this paper, we review the evidence available on the incidence and mechanism of hypertension in prostate cancer patients. In addition, we provide recommendations on the assessment, treatment, and future directions for hypertension management in the prostate cancer population. We propose an individualized goal for blood pressure in prostate cancer patients, balancing the target goal of 130/80 mmHg with common comorbidities of frailty, orthostatic symptoms, and imbalance in this population. The presence of additional comorbidities (myocardial infarction, heart failure, renal disease, diabetes) can assist in preference of anti-hypertensive drugs.
More Related Videos
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Hypertension II: Pathophysiology
Hypertension I: Introduction
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Nursing Assessment of the Genitourinary System I: Health History

